Literature DB >> 32272502

The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance.

Renee B Chang1,2, Gregory L Beatty1,2.   

Abstract

The immune system is a vital determinant of cancer and shapes its trajectory. Notably, the immune reaction to cancer harbors dual potential for suppressing or promoting cancer development and progression. This polarity of the immune response is determined, in part, by the character of the interplay between innate and adaptive immunity. On the one hand, the innate immune compartment is a necessary proponent of cancer immunity by supporting an immunostimulatory state that enables T cell immunosurveillance. However, in the setting of cancer, innate immune cells are commonly polarized with immune-suppressive properties and as a result, orchestrate a tolerogenic niche that interferes with the cytotoxic potential of tumor antigen-specific T cells. Here, we discuss the role of innate immunity as a positive and negative regulator of adaptive immunosurveillance; moreover, we highlight how tumor cells may skew leukocytes toward an immunosuppressive state and, as such, subvert the phenotypic plasticity of the immune compartment to advance disease progression. These observations establish the precedent for novel therapeutic strategies that aim to restore the tumor microenvironment to an immunoreactive state and, in doing so, condition and maintain the immunogenicity of tumors to yield deep and durable responses to immunotherapy. ©2020 Society for Leukocyte Biology.

Entities:  

Keywords:  T cells; cancer; conditioning therapy; immune evasion; immunotherapy; maintenance therapy; myeloid cells

Mesh:

Year:  2020        PMID: 32272502      PMCID: PMC7377219          DOI: 10.1002/JLB.3MIR0320-475R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  158 in total

Review 1.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

2.  Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance.

Authors:  Gregory L Beatty; Shabnam Eghbali; Rebecca Kim
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 3.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.

Authors:  Mark J Smyth; Gavin P Dunn; Robert D Schreiber
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

4.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

Review 5.  Dendritic Cells and Cancer Immunity.

Authors:  Alycia Gardner; Brian Ruffell
Journal:  Trends Immunol       Date:  2016-10-25       Impact factor: 16.687

Review 6.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

Review 7.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2016-01-31       Impact factor: 16.687

8.  Extracellular ATP drives systemic inflammation, tissue damage and mortality.

Authors:  A Cauwels; E Rogge; B Vandendriessche; S Shiva; P Brouckaert
Journal:  Cell Death Dis       Date:  2014-03-06       Impact factor: 8.469

9.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

10.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.

Authors:  Nicholas McGranahan; Rachel Rosenthal; Crispin T Hiley; Andrew J Rowan; Thomas B K Watkins; Gareth A Wilson; Nicolai J Birkbak; Selvaraju Veeriah; Peter Van Loo; Javier Herrero; Charles Swanton
Journal:  Cell       Date:  2017-10-26       Impact factor: 41.582

View more
  13 in total

1.  Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation.

Authors:  Lauren E Milling; Daniel Garafola; Yash Agarwal; Shengwei Wu; Ayush Thomas; Nathan Donahue; Josetta Adams; Nikki Thai; Heikyung Suh; Darrell J Irvine
Journal:  Cancer Immunol Res       Date:  2021-10-22       Impact factor: 11.151

2.  Single-cell profiling of microenvironment components by spatial localization in pancreatic ductal adenocarcinoma.

Authors:  Song Han; Dongtao Fu; Gerik W Tushoski; Lingsong Meng; Kelly M Herremans; Andrea N Riner; Thomas J Geoge; Zhiguang Huo; Steven J Hughes
Journal:  Theranostics       Date:  2022-06-27       Impact factor: 11.600

Review 3.  Mapping and Validation of scRNA-Seq-Derived Cell-Cell Communication Networks in the Tumor Microenvironment.

Authors:  Kate Bridges; Kathryn Miller-Jensen
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

Review 4.  The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches.

Authors:  Anna Koumarianou; Jose Duran-Moreno
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

5.  Circulating immune parameters-based nomogram for predicting malignancy in laryngeal neoplasm.

Authors:  Min Chen; Yi Fang; Yue Yang; Pei-Jie He; Lei Cheng; Hai-Tao Wu
Journal:  World J Clin Cases       Date:  2021-01-26       Impact factor: 1.337

Review 6.  Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment.

Authors:  Théo Accogli; Mélanie Bruchard; Frédérique Végran
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

Review 7.  Engineering Macrophages via Nanotechnology and Genetic Manipulation for Cancer Therapy.

Authors:  Xiaoling Ding; Xinchen Sun; Huihui Cai; Lei Wu; Ying Liu; Yu Zhao; Dingjingyu Zhou; Guiping Yu; Xiaorong Zhou
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

8.  ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.

Authors:  Michael Merker; Juliane Wagner; Hermann Kreyenberg; Catrin Heim; Laura M Moser; Winfried S Wels; Halvard Bonig; Zoltán Ivics; Evelyn Ullrich; Thomas Klingebiel; Peter Bader; Eva Rettinger
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561

Review 9.  Aspartate β-hydroxylase as a target for cancer therapy.

Authors:  Madiha Kanwal; Michal Smahel; Mark Olsen; Jana Smahelova; Ruth Tachezy
Journal:  J Exp Clin Cancer Res       Date:  2020-08-18

10.  Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions.

Authors:  Holly Maulhardt; Alyson Marin; Holly Hesseltine; Gere diZerega
Journal:  Med Oncol       Date:  2021-07-31       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.